Next generation sequencing is performed using ThermoFisher Oncomine Myeloid Research Panel on the Thermofisher Ion GeneStudio S5 instrument.

Next generation sequencing results are reported on APEX and a copy of report is sent by email to requesting clinicians. Please ensure details are included on NGS request form.

A myeloid NGS panel is available to be performed on the following patient categories:

• Treatment eligible patient with acute myeloid leukaemia

• Transplant eligible patient with a diagnosis of myelodysplastic syndrome or primary myelofibrosis

• For differentiation of hypoplastic MDS and aplastic anaemia

• Atypical myeloproliferative neoplasm (“triple negative” PMF, MDS/MPN overlap)

• Relapse AML patient to provide therapeutic information

Please specify to which category the patient belongs when requesting.

For details of genes and fusion partners which are available for assessment, please refer to Next Generation Sequencing.

For clinical advice on appropriate investigations and advice for the interpretation of test results, please contact us​.